Payment overview · 2025
General Payments
$92.39
4 reported records · 4 companies
Healthcare provider profile · identity verified
John M Butler, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MEADOWBROOK, PA · NPI 1629049606
Verified facts
What the public records show
CMS Open Payments records show John M Butler, MD received $92.39 in general payments during 2025 across 4 reported records.
Dexcom, Inc. accounted for 42.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $39.26 | 42.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.25 | 20.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.20 | 18.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $16.68 | 18.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $92.39 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $39.26 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $16.68 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
87 | 87 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
190 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
26 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 731 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 93 |
| Losartan Potassium | Losartan Potassium | 327 | 88 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 308 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 247 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 220 | 68 |
| Lisinopril | Lisinopril | 216 | 51 |
| Eliquis | Apixaban | 190 | 38 |
| Simvastatin | Simvastatin | 167 | 44 |
| Furosemide | Furosemide | 161 | 46 |
| Carvedilol | Carvedilol | 160 | 37 |
| Metformin Hcl | Metformin Hcl | 146 | 45 |
| Alprazolam | Alprazolam | 145 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 135 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 48 |
| Trazodone Hcl | Trazodone Hcl | 119 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 34 |
| Celecoxib | Celecoxib | 113 | 44 |
| Jardiance | Empagliflozin | 111 | 32 |
| Tramadol Hcl | Tramadol Hcl | 106 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 25 |
| Omeprazole | Omeprazole | 101 | 28 |
| Lorazepam | Lorazepam | 99 | 44 |
| Glimepiride | Glimepiride | 97 | 25 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 87 | 87 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 84 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 20 |
| Donepezil Hcl | Donepezil Hcl | 75 | 12 |
| Famotidine | Famotidine | 75 | 22 |
| Pregabalin | Pregabalin | 72 | 20 |
| Januvia | Sitagliptin Phosphate | 70 | 18 |
| Ezetimibe | Ezetimibe | 68 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 23 |
| Alendronate Sodium | Alendronate Sodium | 63 | 17 |
| Potassium Chloride | Potassium Chloride | 63 | 18 |
| Bupropion Xl | Bupropion Hcl | 61 | 16 |
| Meloxicam | Meloxicam | 59 | 15 |
| Mirtazapine | Mirtazapine | 57 | 19 |
| Cefuroxime | Cefuroxime Axetil | 56 | 44 |
| Allopurinol | Allopurinol | 55 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 23 |
| Gabapentin | Gabapentin | 51 | 16 |
| Sertraline Hcl | Sertraline Hcl | 51 | 14 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 50 | 50 |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | 12 |
| Ozempic | Semaglutide | 40 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 37 | 34 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 28 |
| Atenolol | Atenolol | 28 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 26 | 25 |
| Prednisone | Prednisone | 26 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 15 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 12 |
| Valsartan | Valsartan | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 14 |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | 11 |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $92.39 · 4 records | Dexcom, Inc. | Dexcom G6 Transmitter, NURTEC ODT, Veozah, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error